SCHEMBL6038674

SCHEMBL6038674

Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2OCCn2cccn2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.58
KMT2A Q03164 7/20 0.58
KDM4E B2RXH2 8/20 0.56
HSD17B10 Q99714 3/20 0.56
LMNA P02545 2/20 0.56
POLB P06746 2/20 0.50
NPSR1 Q6W5P4 1/20 0.47
RXFP1 Q9HBX9 1/20 0.45
ALDH1A1 P00352 5/20 0.45
MAPT P10636 5/20 0.45
HPGD P15428 3/20 0.45
TSHR P16473 1/20 0.45
CASP1 P29466 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MCL1 Q07820 1/20 0.44
TP53 P04637 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038935 0.92 KDM4E (0.64) MEN1KMT2AKDM4EHSD17B10LMNA
SCHEMBL6038548 0.90 MEN1 (0.58) MEN1KMT2AKDM4EHSD17B10LMNA
SCHEMBL6038855 0.89 KDM4E (0.53) MEN1KMT2AKDM4EHSD17B10LMNA
SCHEMBL6039127 0.86 RXFP1 (0.51) MEN1KMT2AKDM4EHSD17B10LMNA
SCHEMBL6038633 0.85 KMT2A (0.46) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL6039203 0.81 MEN1 (0.56) MEN1KMT2AKDM4EHSD17B10LMNA
SCHEMBL6038811 0.80 MEN1 (0.55) MEN1KMT2AKDM4EHSD17B10LMNA
SCHEMBL6038390 0.80 KDM4E (0.65) MEN1KMT2AKDM4EHSD17B10LMNA
SCHEMBL6038901 0.79 MEN1 (0.54) MEN1KMT2AKDM4EHSD17B10LMNA
SCHEMBL6038850 0.79 KMT2A (0.64) MEN1KMT2AKDM4EHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 MEN1 2431/4885KMT2A 4190/4885KDM4E 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.